Barclays analyst Luke Sergott raised the firm's price target on 10x Genomics to $40 from $30 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science and diagnostic tools space as part of a Q2 preview. Tools are "gaining favor among healthcare subsectors," a trend that is likely to continue into earnings, the analyst tells investors in a research note. Barclays expects in-line to modest beats in Q2 for the group.
